amantadine has been researched along with Parkinsonian Disorders in 38 studies
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Potential neuroprotective activity of the novel antiparkinsonian drug hemantane (hydrochloride N-2-(adamantyl)-hexamethylenimine) in comparison to amantadine has been studied in various regimes of administration on human neuroblastoma SH-SY5Y cell line injury induced by 6-hydroxydopamine (6-OHDA), which is used as in vitro model of dopaminergic neurons for Parkinson's disease." | 7.83 | [COMPARISON OF CYTOPROTECTIVE EFFECTS OF HEMANTANE AND AMANTADINE UNDER CONDITIONS OF 6-HYDROXYDOPAMINE NEUROTOXIN ACTION ON CULTURED HUMAN NEUROBLASTOMA CELLS]. ( Antipova, TA; Logvinov, IO; Nepoklonov, AV; Valdman, EA, 2016) |
| "Potential neuroprotective activity of the novel antiparkinsonian drug hemantane (hydrochloride N-2-(adamantyl)-hexamethylenimine) in comparison to amantadine has been studied in various regimes of administration on human neuroblastoma SH-SY5Y cell line injury induced by 6-hydroxydopamine (6-OHDA), which is used as in vitro model of dopaminergic neurons for Parkinson's disease." | 3.83 | [COMPARISON OF CYTOPROTECTIVE EFFECTS OF HEMANTANE AND AMANTADINE UNDER CONDITIONS OF 6-HYDROXYDOPAMINE NEUROTOXIN ACTION ON CULTURED HUMAN NEUROBLASTOMA CELLS]. ( Antipova, TA; Logvinov, IO; Nepoklonov, AV; Valdman, EA, 2016) |
| "Amantadine is an antiparkinsonian medication scarcely associated with PHS." | 2.72 | Parkinsonism-hyperpyrexia Syndrome After Amantadine Withdrawal: Case Report and Review of the Literature. ( Dos Santos, DT; Imthon, AK; Pille, A; Schumacher-Schuh, AF; Strelow, MZ, 2021) |
| "Our patient had developed overt parkinsonism presenting with a resting tremor, expressionless face, and lack of blinking along with marked cogwheel rigidity and a stooped, slow gait." | 2.43 | Extrapyramidal parkinsonism complicating acute organophosphate insecticide poisoning. ( Bar-Joseph, G; Bentur, Y; Cahana, A; Hershman, E; Shahar, E, 2005) |
| "There are many causes of parkinsonism such as drug induced parkinsonism, subcortical vascular disease, and multisystem atrophy." | 2.42 | [Diagnosis and treatment of Parkinson's syndrome. What is important for the general practitioner?]. ( Ceballos-Baumann, A, 2003) |
| "Dopamine replacement therapy using L-3,4-dihydroxyphenylalanine (L-DOPA) is a gold standard treatment in patients with Parkinson's disease (PD); however, chronic administration of L-DOPA causes excessive involuntary movements called L-DOPA-induced dyskinesia." | 1.56 | Ameliorative effects of a phosphodiesterase 10A inhibitor, MR1916 on L-DOPA-induced dyskinesia in parkinsonian rats. ( Arakawa, K; Maehara, S; Yuge, N, 2020) |
| "Amantadine (10 mg/kg PO) was tested as a positive control." | 1.56 | The selective 5-HT ( Brotchie, JM; Depoortere, R; Fox, SH; Johnston, TH; Newman-Tancredi, A, 2020) |
| "Amantadine may cause RVOT-VT as well as other cardiac arrhythmias." | 1.42 | Right ventricular outflow tract tachycardia after an initial dose of amantadine. ( Çetinkal, G; Doğan, SM; Kocaş, C; Türkmen, Y, 2015) |
| "Although neurological manifestations of typhoid fever was thought to be obsolete from modern world, emergence of multidrug resistant typhoid bacilli and reporting of outbreak of typhoid fever with a range of early neuropsychiatric manifestations from various parts of world has led clinicians and investigators to re-evaluate the clinical spectrum of this endemic sinister disease." | 1.39 | Catatonia and parkinsonism as a sequelae of typhoid fever: a rare experience. ( Dutta, A; Rana, S; Talukdar, A; Talukdar, P, 2013) |
| " The chronic administration of these drugs together with amantadine (20 mg/kg) accelerates the onset of latency and increases the magnitude of dyskinesia." | 1.37 | [Comparative study of amantadine and hemantane effects on development of levodopa-induced dyskinesia in rat model of parkinsonian syndrome]. ( Ivanova, EA; Kapitsa, IG; Kokshenev, II; Nepoklonov, AV; Val'dman, EA; Voronina, TA, 2011) |
| "Methanol poisoning is an uncommon but potent central nervous system toxin." | 1.32 | Methanol poisoning: diagnosis and management. A case report. ( Ahmed, S; Ashebu, SD; Bitar, ZI, 2004) |
| "Once a parkinsonian syndrome was diagnosed, she was given amantadine therapy with complete recovery." | 1.31 | Extra-pyramidal parkinsonism complicating organophosphate insecticide poisoning. ( Andraws, J; Shahar, E, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.63) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (31.58) | 29.6817 |
| 2010's | 17 (44.74) | 24.3611 |
| 2020's | 8 (21.05) | 2.80 |
| Authors | Studies |
|---|---|
| Bourque, M | 3 |
| Grégoire, L | 3 |
| Patel, W | 3 |
| Dickens, D | 3 |
| Snodgrass, R | 3 |
| Di Paolo, T | 3 |
| Rentsch, P | 1 |
| Stayte, S | 1 |
| Egan, T | 1 |
| Clark, I | 1 |
| Vissel, B | 1 |
| Arakawa, K | 1 |
| Yuge, N | 1 |
| Maehara, S | 1 |
| Shen, W | 1 |
| Ren, W | 1 |
| Zhai, S | 1 |
| Yang, B | 1 |
| Vanoye, CG | 1 |
| Mitra, A | 1 |
| George, AL | 1 |
| Surmeier, DJ | 1 |
| Wiwanitkit, V | 1 |
| Aranda-Abreu, GE | 1 |
| Depoortere, R | 1 |
| Johnston, TH | 2 |
| Fox, SH | 2 |
| Brotchie, JM | 2 |
| Newman-Tancredi, A | 1 |
| Dos Santos, DT | 1 |
| Imthon, AK | 1 |
| Strelow, MZ | 1 |
| Pille, A | 1 |
| Schumacher-Schuh, AF | 1 |
| McGarry, A | 1 |
| Biglan, K | 1 |
| Talukdar, P | 1 |
| Dutta, A | 1 |
| Rana, S | 1 |
| Talukdar, A | 1 |
| Kocaş, C | 1 |
| Türkmen, Y | 1 |
| Çetinkal, G | 1 |
| Doğan, SM | 1 |
| Chattopadhyaya, I | 1 |
| Gupta, S | 1 |
| Mohammed, A | 1 |
| Mushtaq, N | 1 |
| Chauhan, S | 1 |
| Ghosh, S | 2 |
| Park, H | 1 |
| Jeon, BS | 1 |
| Shin, JH | 1 |
| Park, SH | 1 |
| Zhang, LL | 1 |
| Canning, SD | 1 |
| Wang, XP | 1 |
| Tada, H | 1 |
| Ogihara, T | 1 |
| Nakamura, T | 1 |
| Sasayama, D | 1 |
| Sugiyama, N | 1 |
| Takahashi, Y | 1 |
| Washizuka, S | 1 |
| Amano, N | 1 |
| Logvinov, IO | 2 |
| Antipova, TA | 2 |
| Nepoklonov, AV | 2 |
| Valdman, EA | 1 |
| Ghaffariyeh, A | 1 |
| Honarpisheh, N | 1 |
| Spinnewyn, B | 1 |
| Charnet, C | 1 |
| Cornet, S | 1 |
| Roubert, V | 1 |
| Chabrier, PE | 1 |
| Auguet, M | 1 |
| Zimin, IA | 1 |
| Kovalev, GI | 1 |
| Ossola, B | 1 |
| Schendzielorz, N | 1 |
| Chen, SH | 1 |
| Bird, GS | 1 |
| Tuominen, RK | 1 |
| Männistö, PT | 1 |
| Hong, JS | 1 |
| Kapitsa, IG | 1 |
| Ivanova, EA | 1 |
| Kokshenev, II | 1 |
| Voronina, TA | 1 |
| Val'dman, EA | 1 |
| Paquette, MA | 1 |
| Martinez, AA | 1 |
| Macheda, T | 1 |
| Meshul, CK | 1 |
| Johnson, SW | 1 |
| Berger, SP | 1 |
| Giuffrida, A | 1 |
| Breger, LS | 1 |
| Dunnett, SB | 1 |
| Lane, EL | 1 |
| Yeh, CH | 1 |
| Lin, SF | 1 |
| Lin, CY | 1 |
| Chen, CY | 1 |
| Chow, KC | 1 |
| Bezard, E | 1 |
| Tronci, E | 1 |
| Pioli, EY | 1 |
| Li, Q | 1 |
| Porras, G | 1 |
| Björklund, A | 1 |
| Carta, M | 2 |
| Skolimowski, J | 1 |
| Kochman, A | 1 |
| Gebicka, L | 1 |
| Metodiewa, D | 1 |
| Ceballos-Baumann, A | 1 |
| Bitar, ZI | 1 |
| Ashebu, SD | 1 |
| Ahmed, S | 1 |
| Lundblad, M | 1 |
| Usiello, A | 1 |
| Håkansson, K | 1 |
| Fisone, G | 1 |
| Cenci, MA | 1 |
| Shahar, E | 2 |
| Bentur, Y | 1 |
| Bar-Joseph, G | 1 |
| Cahana, A | 1 |
| Hershman, E | 1 |
| Visanji, NP | 1 |
| Gomez-Ramirez, J | 1 |
| Pires, D | 1 |
| Voon, V | 1 |
| Fann, WE | 1 |
| Lake, CR | 1 |
| Shiio, Y | 1 |
| Fredriksson, A | 1 |
| Danysz, W | 1 |
| Quack, G | 1 |
| Archer, T | 1 |
| Andraws, J | 1 |
| Brooks, DJ | 1 |
| Finsterer, J | 1 |
6 reviews available for amantadine and Parkinsonian Disorders
| Article | Year |
|---|---|
Parkinsonism-hyperpyrexia Syndrome After Amantadine Withdrawal: Case Report and Review of the Literature.
Topics: Aged; Amantadine; Antiparkinson Agents; Female; Humans; Neuroleptic Malignant Syndrome; Parkinson Di | 2021 |
Freezing of Gait in Parkinsonism and its Potential Drug Treatment.
Topics: Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Botulinum Toxins; Droxidopa; Gait Disorde | 2016 |
[Diagnosis and treatment of Parkinson's syndrome. What is important for the general practitioner?].
Topics: Aged; Amantadine; Antiparkinson Agents; Apomorphine; Botulinum Toxins; Catechols; Cholinesterase Inh | 2003 |
Extrapyramidal parkinsonism complicating acute organophosphate insecticide poisoning.
Topics: Acute Disease; Adolescent; Amantadine; Antiparkinson Agents; Basal Ganglia Diseases; Dimethoate; Hum | 2005 |
[Drug-induced parkinsonism].
Topics: Amantadine; Antiparkinson Agents; Antipsychotic Agents; Benzamides; Butyrophenones; Calcium Channel | 2007 |
[Parkinson disease: diagnostic and therapeutic criteria].
Topics: Activities of Daily Living; Adult; Aged; Amantadine; Antiparkinson Agents; Bromocriptine; Diagnosis, | 2001 |
1 trial available for amantadine and Parkinsonian Disorders
| Article | Year |
|---|---|
On the coexistence of parkinsonism and tardive dyskinesia.
Topics: Amantadine; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Induced; | 1974 |
31 other studies available for amantadine and Parkinsonian Disorders
| Article | Year |
|---|---|
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
Targeting the cannabinoid receptor CB2 in a mouse model of l-dopa induced dyskinesia.
Topics: Amantadine; Animals; Antiparkinson Agents; Camphanes; Cannabinoid Receptor Agonists; Cannabinoids; D | 2020 |
Ameliorative effects of a phosphodiesterase 10A inhibitor, MR1916 on L-DOPA-induced dyskinesia in parkinsonian rats.
Topics: Administration, Oral; Amantadine; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; D | 2020 |
Striatal Kir2 K+ channel inhibition mediates the antidyskinetic effects of amantadine.
Topics: Amantadine; Animals; Antiparkinson Agents; CHO Cells; Corpus Striatum; Cricetulus; Dyskinesia, Drug- | 2020 |
Amantadine, COVID-19 and Parkinsonism.
Topics: Amantadine; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Pandemics; Parkinsonian Disor | 2020 |
Response to: Amantadine, COVID-19 and Parkinsonism.
Topics: Amantadine; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Pandemics; Parkinsonian Disor | 2020 |
The selective 5-HT
Topics: Amantadine; Animals; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levo | 2020 |
Improvement of freezing of gait with amantadine in a patient with oculopharyngeal muscular dystrophy and Parkinsonism.
Topics: Aged; Amantadine; Antiparkinson Agents; Freezing Reaction, Cataleptic; Gait Disorders, Neurologic; H | 2013 |
Catatonia and parkinsonism as a sequelae of typhoid fever: a rare experience.
Topics: Adolescent; Amantadine; Antiparkinson Agents; Antipsychotic Agents; Benzodiazepines; Benzothiazoles; | 2013 |
Right ventricular outflow tract tachycardia after an initial dose of amantadine.
Topics: Amantadine; Electrocardiography; Female; Heart Ventricles; Humans; Middle Aged; Parkinsonian Disorde | 2015 |
Neuroprotective effect of Spirulina fusiform and amantadine in the 6-OHDA induced Parkinsonism in rats.
Topics: Amantadine; Animals; Dietary Supplements; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorder | 2015 |
A patient with 41 CAG repeats in SCA17 presenting with parkinsonism and chorea.
Topics: Amantadine; Antiparkinson Agents; Benzothiazoles; Brain; Chorea; Humans; Levodopa; Male; Middle Aged | 2016 |
A case of severe parkinsonism in an elderly person induced by valproic acid.
Topics: Aged; Amantadine; Anticonvulsants; Brain; Dose-Response Relationship, Drug; Female; Humans; Magnetic | 2017 |
[COMPARISON OF CYTOPROTECTIVE EFFECTS OF HEMANTANE AND AMANTADINE UNDER CONDITIONS OF 6-HYDROXYDOPAMINE NEUROTOXIN ACTION ON CULTURED HUMAN NEUROBLASTOMA CELLS].
Topics: Adamantane; Amantadine; Cell Line, Tumor; Cytoprotection; Dose-Response Relationship, Drug; Humans; | 2016 |
Amantadine-associated corneal edema.
Topics: Aged; Amantadine; Anti-Inflammatory Agents; Antiparkinson Agents; Corneal Edema; Female; Humans; Oph | 2010 |
An improved model to investigate the efficacy of antidyskinetic agents in hemiparkinsonian rats.
Topics: Adenosine A2 Receptor Antagonists; Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Bens | 2011 |
[A comparative study of hemantane and amantadine effects on dopamine transporter expression in brain of normal and MPTP-treated C57BL/6 mice].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adamantane; Amantadine; Animals; Antiparkinson Agents; | 2011 |
Amantadine protects dopamine neurons by a dual action: reducing activation of microglia and inducing expression of GDNF in astroglia [corrected].
Topics: Amantadine; Animals; Animals, Newborn; Astrocytes; Cells, Cultured; Coculture Techniques; Dopamine; | 2011 |
[Comparative study of amantadine and hemantane effects on development of levodopa-induced dyskinesia in rat model of parkinsonian syndrome].
Topics: Adamantane; Amantadine; Animals; Behavior, Animal; Benserazide; Disease Models, Animal; Dyskinesia, | 2011 |
Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors.
Topics: Amantadine; Animals; Antiparkinson Agents; Cycloserine; Dextromethorphan; Dopamine Agents; Dyskinesi | 2012 |
Comparison of rating scales used to evaluate L-DOPA-induced dyskinesia in the 6-OHDA lesioned rat.
Topics: Adrenergic Agents; Amantadine; Animals; Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-In | 2013 |
Acute onset of parkinsonism with reversible course after H1N1 vaccination: insight from a young lady.
Topics: Adolescent; Amantadine; Benzothiazoles; Drug Therapy, Combination; Female; Humans; Influenza A Virus | 2012 |
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
Topics: Amantadine; Amphetamine; Animals; Apomorphine; Disease Models, Animal; Dopamine Agents; Dyskinesia, | 2013 |
Synthesis and antioxidant activity evaluation of novel antiparkinsonian agents, aminoadamantane derivatives of nitroxyl free radical.
Topics: Adamantane; Amantadine; Animals; Antioxidants; Antiparkinson Agents; Brain; Dopamine; Female; Free R | 2003 |
Methanol poisoning: diagnosis and management. A case report.
Topics: Adult; Amantadine; Antiparkinson Agents; Humans; Male; Methanol; Parkinsonian Disorders; Solvents; T | 2004 |
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
Topics: Adenosine A2 Receptor Agonists; Adrenergic Agents; Amantadine; Animals; Antiparkinson Agents; Basal | 2005 |
Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Apomorphine | 2006 |
Co-administration of memantine and amantadine with sub/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dizocilpine | 2001 |
Extra-pyramidal parkinsonism complicating organophosphate insecticide poisoning.
Topics: Adolescent; Amantadine; Antiparkinson Agents; Basal Ganglia Diseases; Female; Humans; Insecticides; | 2001 |
Diagnosis and management of atypical parkinsonian syndromes.
Topics: Amantadine; Antiparkinson Agents; Brain; Cholinergic Antagonists; Diagnosis, Differential; Diagnosti | 2002 |
Parkinson syndrome as a manifestation of mitochondriopathy.
Topics: Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Biopsy; DNA, Mitochondrial; Dopamine; Ele | 2002 |